Welcome to our dedicated page for Dyne Therapeutics news (Ticker: DYN), a resource for investors and traders seeking the latest updates and insights on Dyne Therapeutics stock.
Dyne Therapeutics, Inc. (Nasdaq: DYN) is a pioneering biotechnology company based in Waltham, Massachusetts, that is dedicated to developing therapeutic solutions for genetically driven muscle diseases. Founded in 2017, Dyne Therapeutics leverages its proprietary FORCE™ platform to overcome the delivery challenges associated with modern oligonucleotide therapeutics, aiming to provide life-transforming treatments for patients.
Dyne's primary focus is on advancing therapeutics for muscle disorders such as Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD). The company’s lead programs include DYNE-101 for DM1 and DYNE-251 for DMD, both of which have shown promising clinical results. Recent clinical trials have demonstrated dose-dependent splicing correction, improvement in muscle strength, and favorable safety profiles.
In January 2024, Dyne announced the successful completion of a $345 million public offering, extending its cash runway through 2025. This funding enables the company to advance its clinical programs and pursue expedited regulatory pathways to bring its therapies to market more swiftly.
Dyne’s recent milestones include:
- Positive clinical data from the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1 patients, showing dose-dependent muscle delivery and splicing correction.
- Meaningful improvement in functional endpoints and dystrophin expression in the Phase 1/2 DELIVER trial of DYNE-251 in DMD patients.
- Ongoing efforts to enhance dosing regimens and seek accelerated approval pathways with global regulatory authorities.
With a robust pipeline and a dedicated team, Dyne is committed to addressing the unmet needs of patients with rare muscle diseases, aiming to transform their treatment landscape and improve their quality of life.
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the closing of its underwritten public offering of 19,722,500 shares of its common stock at a public offering price of $17.50 per share, resulting in gross proceeds of approximately $345.1 million. The offering was made by means of a prospectus supplement and accompanying prospectus that form a part of the registration statements. The company's focus on advancing innovative life-transforming therapeutics for genetically driven diseases is evident from this announcement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that Joshua Brumm, president and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The live webcast will be available on the company's website, with a replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share. The gross proceeds to Dyne from the offering are expected to be approximately $300.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.37%
Tags
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) has commenced an underwritten public offering of $175,000,000 of shares of its common stock, with the intention to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with and declared effective by the Securities and Exchange Commission (“SEC”).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.28%
Tags
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) announced positive initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.09%
Tags
-
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m. ET. The company will issue a press release prior to the event. The event will feature presentations and Q&A with leading neuromuscular disease experts. The live webcast will be available on Dyne's website and a replay will be accessible for 90 days. To register for the webcast and replay, visit https://investors.dyne-tx.com/news-and-events/events-and-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.09%
Tags
Rhea-AI Summary
Dyne Therapeutics, Inc. (Nasdaq: DYN) will be presenting at two investor conferences in November, providing live webcasts and replays for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
-
Rhea-AI Summary
Dyne Therapeutics reports financial results for Q3 2023 and provides an update on its ACHIEVE and DELIVER clinical trials. Over 72 patients enrolled and over 300 doses administered. Initial data to be presented at the J.P. Morgan Healthcare Conference in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
-
Rhea-AI Summary
Dyne Therapeutics to present at investor conferences in October
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
Rhea-AI Summary
Dyne Therapeutics receives FDA orphan drug designation for DYNE-101, potential transformative therapy for myotonic dystrophy type 1 (DM1). Initial data from ACHIEVE trial expected in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
FAQ
What is the current stock price of Dyne Therapeutics (DYN)?
The current stock price of Dyne Therapeutics (DYN) is $14.79 as of February 4, 2025.
What is the market cap of Dyne Therapeutics (DYN)?
The market cap of Dyne Therapeutics (DYN) is approximately 1.4B.
What does Dyne Therapeutics, Inc. specialize in?
Dyne Therapeutics specializes in developing therapeutic solutions for genetically driven muscle diseases using its proprietary FORCE™ platform.
What are the main diseases Dyne Therapeutics targets?
Dyne Therapeutics is focused on treating muscle disorders such as Myotonic Dystrophy Type 1 (DM1), Duchenne Muscular Dystrophy (DMD), and Facioscapulohumeral Muscular Dystrophy (FSHD).
What is DYNE-101?
DYNE-101 is an investigational therapeutic for Myotonic Dystrophy Type 1 (DM1) that has shown promising results in clinical trials, including dose-dependent muscle delivery and splicing correction.
What is DYNE-251?
DYNE-251 is an investigational therapeutic for Duchenne Muscular Dystrophy (DMD) that has demonstrated significant dystrophin expression and improvement in functional endpoints in clinical trials.
How is Dyne Therapeutics funded for their projects?
Dyne Therapeutics recently completed a $345 million public offering in January 2024, extending its projected cash runway through 2025.
Where is Dyne Therapeutics headquartered?
Dyne Therapeutics is headquartered in Waltham, Massachusetts.
When was Dyne Therapeutics founded?
Dyne Therapeutics was founded in 2017.
What recent achievements has Dyne Therapeutics made?
Recent achievements include positive clinical data from the ACHIEVE and DELIVER trials, demonstrating favorable safety profiles and functional improvements in DM1 and DMD patients.
What is the FORCE™ platform?
The FORCE™ platform is Dyne Therapeutics' proprietary technology designed to enhance the delivery of disease-modifying therapies to muscle tissue.
Who are the key investors and partners in Dyne Therapeutics?
Key investors and partners include firms like Morgan Stanley, J.P. Morgan, Jefferies, and Stifel, who have participated in recent funding rounds.
Dyne Therapeutics, Inc.
Nasdaq:DYN
DYN Rankings
DYN Stock Data
1.44B
99.29M
0.77%
112.25%
9.24%
Biotechnology
Pharmaceutical Preparations
United States of America
WALTHAM